TrianglePembrolizumab (NCT05583708)
Pembrolizumab trial for Merkel Cell Carcinoma (NCT05583708). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with Merkel-cell cancer that progressed after anti-PD-1 or anti-PD-L1 treatment. Scans must show somatostatin receptors, and measurable cancer must remain.
The idea: combine pembrolizumab with lutetium-177 dotatate infusions. Pembrolizumab helps immune cells attack cancer. Lutetium dotatate binds somatostatin receptors and delivers cell-damaging radiation. Patients receive four treatments, two months apart, and pembrolizumab every six weeks for up to two years. A safety group comes first. Researchers measure tumor shrinkage or disappearance and side effects.
This phase 2 study plans 18 patients. Anna Pavlick leads three recruiting US sites.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.